Generation of MRP2 Efflux Transporter Knock-Out in HepaRG Cell Linemdmitc
MilliporeSigma's Jennifer Pratt recently presented a poster at the 2016 AAPS/ITC Transporter Workshop demonstrating the utility of HepaRG MRP2 Knockout cells for investigating drug-transporter interactions in the liver involving MRP2.
Improved vector design eases cell line development workflow in the CHOZN GS-/...Merck Life Sciences
This poster was presented at ESACT meeting in 2017 in Lausanne, Switzerland. Cell line development for production of monoclonal antibody therapeutics requires an expression vector encoding both the heavy and light chains of the antibody. When expression of the heavy and lights chains is driven by the same promoter, the sequence redundancy can be problematic for verifying the vector sequence, copy number and insertion site in the host cell genome. This poster describes the work done to identify an expression vector that maintains a high level of antibody expression but lacks the sequence similarities, easing the cell line development workflow.
Generation of MRP2 Efflux Transporter Knock-Out in HepaRG Cell Linemdmitc
MilliporeSigma's Jennifer Pratt recently presented a poster at the 2016 AAPS/ITC Transporter Workshop demonstrating the utility of HepaRG MRP2 Knockout cells for investigating drug-transporter interactions in the liver involving MRP2.
Improved vector design eases cell line development workflow in the CHOZN GS-/...Merck Life Sciences
This poster was presented at ESACT meeting in 2017 in Lausanne, Switzerland. Cell line development for production of monoclonal antibody therapeutics requires an expression vector encoding both the heavy and light chains of the antibody. When expression of the heavy and lights chains is driven by the same promoter, the sequence redundancy can be problematic for verifying the vector sequence, copy number and insertion site in the host cell genome. This poster describes the work done to identify an expression vector that maintains a high level of antibody expression but lacks the sequence similarities, easing the cell line development workflow.
pOnebyOne™ are efficient, accurate and flexible Bicistronic Mammalian Expression Kits that contains an Expression Cassette based in 2A sequence breakthrough technology.
Its novel (patent pending) technology allows simultaneous Expression of two Proteins from the same mRNA. Cells transfected with Bicistronic vectors ensure that if one of the Proteins is present, the other one is also present.
Bicistronic Expression vectors are supported on viral elements: the IRES or 2A sequence. IRES has been widely used. It is a relative short sequence, around 600-700 bp, although this length could be a disadvantage in viral vectors where packaging capacity is limited. IRES based Expression vectors are characterized by a non-stoichiometric production of both proteins; generally there is a lower expression of the downstream gene.
Many 2A sequences from several families of viruses have been described for producing multiple polypeptides. 2A mediated cleavage is a universal phenomenon in all eukaryotic cells. With just 20 bp in length, the 2A sequence has been used succesfully to generate multiple proteins in some biological models: plants, zebrafish, transgenic mice or eukaryotic cell lines. Vectors based on 2A produce stoichiometric proportion of both proteins.
Canvax™ offers a ready-to-clone solution of your Gene of Interest, obtained by PCR, onto a wide collection of Bicistronic vectors based on 2A sequence. You can choose among different Promoters, selection Antibiotics or Reporter Genes.
Culture of Renal Proximal Tubule Epithelial Cell Line SA7K Using Extracellula...mdmitc
MilliporeSigma's Toni Steiner recently presented a poster at the 2016 AAPS/ITC Transporter Workshop demonstrating how culture conditions can influence drug transporter expression and activity in renal proximal tubule epithelial cells.
this is a presentation on gene expression vector that includes what is expression vector, how many types of expression vector and difference between cloning and expression vector
Production and purification of Viral vectors for gene and cell therapy appli...Dr. Priyabrata Pattnaik
Presentation at "2016 Osong BioExcellence - Renaissance in Immunotherapy" at South Korea, an event jointly hosted by Kbio Health and Merck on 6th October 2016.
Delivering More Efficient Therapeutic Protein Expression Systems Through Cell...Merck Life Sciences
Historically cell line performance has been enhanced through media, feed and process optimization, primarily through trying to meet the basic nutritional requirements of the cells so that they can sustain high growth and productivity throughout the production runs.
However, the omics (genomics, transciptomics and metabolomics) era, sequencing of the CHO genome and enhancements in genome editing technologies over the past several years have enabled scientists to take a more direct route in cell line optimization through the modification of specific genes that have direct implications on cell culture performance, protein quality attributes and upstream and downstream manufacturing processes. These targets include but are not limited to genes that may be involved in cell cycle regulation, cellular metabolism, cellular transcription and translation, the secretory pathway and protein glycosylation or other post-translational modifications.
In this webinar we will discuss specific genetic modifications that have been made to CHO cell lines and how these modifications can lead to more efficient expression systems.
Recombinant Fab fragments specific for the pfHRPII and pfHSP72 : implications for malaria diagnosis - Parole de junior de la 7e édition du Cours international « Atelier Paludisme » - Ravaoarisoa Elisabeth - Madagascar - elisa@pasteur.mg
Gene Editing: An Essential Tool For Plant BreedingNoreen Fatima
Gene editing to remove the specie barriers. In many crops it have been used for improvement of crops for particular attribute. in this many tools have been used . these tools consist of nucleases that cut the DNA. So that is used for gene regulation, gene knock out and also use for point mutations.
pOnebyOne™ are efficient, accurate and flexible Bicistronic Mammalian Expression Kits that contains an Expression Cassette based in 2A sequence breakthrough technology.
Its novel (patent pending) technology allows simultaneous Expression of two Proteins from the same mRNA. Cells transfected with Bicistronic vectors ensure that if one of the Proteins is present, the other one is also present.
Bicistronic Expression vectors are supported on viral elements: the IRES or 2A sequence. IRES has been widely used. It is a relative short sequence, around 600-700 bp, although this length could be a disadvantage in viral vectors where packaging capacity is limited. IRES based Expression vectors are characterized by a non-stoichiometric production of both proteins; generally there is a lower expression of the downstream gene.
Many 2A sequences from several families of viruses have been described for producing multiple polypeptides. 2A mediated cleavage is a universal phenomenon in all eukaryotic cells. With just 20 bp in length, the 2A sequence has been used succesfully to generate multiple proteins in some biological models: plants, zebrafish, transgenic mice or eukaryotic cell lines. Vectors based on 2A produce stoichiometric proportion of both proteins.
Canvax™ offers a ready-to-clone solution of your Gene of Interest, obtained by PCR, onto a wide collection of Bicistronic vectors based on 2A sequence. You can choose among different Promoters, selection Antibiotics or Reporter Genes.
Culture of Renal Proximal Tubule Epithelial Cell Line SA7K Using Extracellula...mdmitc
MilliporeSigma's Toni Steiner recently presented a poster at the 2016 AAPS/ITC Transporter Workshop demonstrating how culture conditions can influence drug transporter expression and activity in renal proximal tubule epithelial cells.
this is a presentation on gene expression vector that includes what is expression vector, how many types of expression vector and difference between cloning and expression vector
Production and purification of Viral vectors for gene and cell therapy appli...Dr. Priyabrata Pattnaik
Presentation at "2016 Osong BioExcellence - Renaissance in Immunotherapy" at South Korea, an event jointly hosted by Kbio Health and Merck on 6th October 2016.
Delivering More Efficient Therapeutic Protein Expression Systems Through Cell...Merck Life Sciences
Historically cell line performance has been enhanced through media, feed and process optimization, primarily through trying to meet the basic nutritional requirements of the cells so that they can sustain high growth and productivity throughout the production runs.
However, the omics (genomics, transciptomics and metabolomics) era, sequencing of the CHO genome and enhancements in genome editing technologies over the past several years have enabled scientists to take a more direct route in cell line optimization through the modification of specific genes that have direct implications on cell culture performance, protein quality attributes and upstream and downstream manufacturing processes. These targets include but are not limited to genes that may be involved in cell cycle regulation, cellular metabolism, cellular transcription and translation, the secretory pathway and protein glycosylation or other post-translational modifications.
In this webinar we will discuss specific genetic modifications that have been made to CHO cell lines and how these modifications can lead to more efficient expression systems.
Recombinant Fab fragments specific for the pfHRPII and pfHSP72 : implications for malaria diagnosis - Parole de junior de la 7e édition du Cours international « Atelier Paludisme » - Ravaoarisoa Elisabeth - Madagascar - elisa@pasteur.mg
Gene Editing: An Essential Tool For Plant BreedingNoreen Fatima
Gene editing to remove the specie barriers. In many crops it have been used for improvement of crops for particular attribute. in this many tools have been used . these tools consist of nucleases that cut the DNA. So that is used for gene regulation, gene knock out and also use for point mutations.
The emerging CRISPR/Cas9 gene editing technology greatly accelerates the R&D process in life sciences. Here, we briefly introduce CRISPR/Cas9 and its delivery strategies.
Unveiling the Potential of your AAV Gene Therapy: Orthogonal methods to under...Merck Life Sciences
Watch the presentation of this webinar here: https://bit.ly/3pCCjPF
Ensure your Adeno-Associated Virus (AAV) is safe throughout its entire drug development journey. Learn methods that will help you speed to clinic, potentially treating diseases sooner and with greater effectiveness.
The potential of gene therapies to cure previously untreatable diseases has spurred the development of novel drugs, including those based on Adeno-Associated Virus (AAV). As with all biopharmaceuticals, it is important to identify and monitor the critical quality attributes (CQAs) of these products to ensure their safety and efficacy.
In this webinar, we will present a range of orthogonal methods to understand and define the CQAs of AAV products. These include assays for the confirmation of capsid protein identity and quantity, as well as the characterization of important product-related impurities, such as aggregates. Together these methods represent a comprehensive analytical testing package to support the characterization and lot release of AAV products.
In this webinar, you will learn:
• How to identify and monitor the critical quality attributes (CQAs) of your AAV therapy
• What assays to utilize to confirm capsid protein identity and quantity
• Why you need look to product characterization to identify and remove important product-related impurities
Unveiling the Potential of your AAV Gene Therapy: Orthogonal methods to under...MilliporeSigma
Watch the presentation of this webinar here: https://bit.ly/3pCCjPF
Ensure your Adeno-Associated Virus (AAV) is safe throughout its entire drug development journey. Learn methods that will help you speed to clinic, potentially treating diseases sooner and with greater effectiveness.
The potential of gene therapies to cure previously untreatable diseases has spurred the development of novel drugs, including those based on Adeno-Associated Virus (AAV). As with all biopharmaceuticals, it is important to identify and monitor the critical quality attributes (CQAs) of these products to ensure their safety and efficacy.
In this webinar, we will present a range of orthogonal methods to understand and define the CQAs of AAV products. These include assays for the confirmation of capsid protein identity and quantity, as well as the characterization of important product-related impurities, such as aggregates. Together these methods represent a comprehensive analytical testing package to support the characterization and lot release of AAV products.
In this webinar, you will learn:
• How to identify and monitor the critical quality attributes (CQAs) of your AAV therapy
• What assays to utilize to confirm capsid protein identity and quantity
• Why you need look to product characterization to identify and remove important product-related impurities
See the Whole Picture: Using SV-AUC for Empty/Full AAV Capsid AnalysisMilliporeSigma
Watch this webinar here: https://bit.ly/31ZZM3n
Join this webinar for key insights on using the SV-AUC assay for empty/full analysis of your AAV viral vector. We’ll cover the technical requirements for this assay, data interpretation, and finally how this assay fits into the larger picture of AAV characterization.
Recombinant adeno-associated viruses (AAV) are widely used as gene transfer vectors. However, AAV production generates mixed populations of viral capsids containing either complete viral vector genome (full capsids); partially filled, and those lacking the viral genome (empty capsids). Sedimentation Velocity Analytical Ultracentrifugation (SV-AUC) offers a robust, accurate, and consistent method for characterizing empty/full AAV capsid composition. In this webinar we will review the key technical requirements for performing an AUC assay as well as analysis and data interpretation of the results generated.
In this webinar, you will learn:
• Regulatory expectations for empty/full analysis
• Key technical requirements for running an AUC assay and how to interpret the data from the results generated
• How the AUC assay fits into the larger picture of AAV characterization
See the Whole Picture: Using SV-AUC for Empty/Full AAV Capsid AnalysisMerck Life Sciences
Watch this webinar here: https://bit.ly/31ZZM3n
Join this webinar for key insights on using the SV-AUC assay for empty/full analysis of your AAV viral vector. We’ll cover the technical requirements for this assay, data interpretation, and finally how this assay fits into the larger picture of AAV characterization.
Recombinant adeno-associated viruses (AAV) are widely used as gene transfer vectors. However, AAV production generates mixed populations of viral capsids containing either complete viral vector genome (full capsids); partially filled, and those lacking the viral genome (empty capsids). Sedimentation Velocity Analytical Ultracentrifugation (SV-AUC) offers a robust, accurate, and consistent method for characterizing empty/full AAV capsid composition. In this webinar we will review the key technical requirements for performing an AUC assay as well as analysis and data interpretation of the results generated.
In this webinar, you will learn:
• Regulatory expectations for empty/full analysis
• Key technical requirements for running an AUC assay and how to interpret the data from the results generated
• How the AUC assay fits into the larger picture of AAV characterization
This presentation covers a general introduction to expression vector, its components, types, and its application. Then it covers some of the expression system with examples.
THE IMPORTANCE OF MARTIAN ATMOSPHERE SAMPLE RETURN.Sérgio Sacani
The return of a sample of near-surface atmosphere from Mars would facilitate answers to several first-order science questions surrounding the formation and evolution of the planet. One of the important aspects of terrestrial planet formation in general is the role that primary atmospheres played in influencing the chemistry and structure of the planets and their antecedents. Studies of the martian atmosphere can be used to investigate the role of a primary atmosphere in its history. Atmosphere samples would also inform our understanding of the near-surface chemistry of the planet, and ultimately the prospects for life. High-precision isotopic analyses of constituent gases are needed to address these questions, requiring that the analyses are made on returned samples rather than in situ.
Multi-source connectivity as the driver of solar wind variability in the heli...Sérgio Sacani
The ambient solar wind that flls the heliosphere originates from multiple
sources in the solar corona and is highly structured. It is often described
as high-speed, relatively homogeneous, plasma streams from coronal
holes and slow-speed, highly variable, streams whose source regions are
under debate. A key goal of ESA/NASA’s Solar Orbiter mission is to identify
solar wind sources and understand what drives the complexity seen in the
heliosphere. By combining magnetic feld modelling and spectroscopic
techniques with high-resolution observations and measurements, we show
that the solar wind variability detected in situ by Solar Orbiter in March
2022 is driven by spatio-temporal changes in the magnetic connectivity to
multiple sources in the solar atmosphere. The magnetic feld footpoints
connected to the spacecraft moved from the boundaries of a coronal hole
to one active region (12961) and then across to another region (12957). This
is refected in the in situ measurements, which show the transition from fast
to highly Alfvénic then to slow solar wind that is disrupted by the arrival of
a coronal mass ejection. Our results describe solar wind variability at 0.5 au
but are applicable to near-Earth observatories.
Nutraceutical market, scope and growth: Herbal drug technologyLokesh Patil
As consumer awareness of health and wellness rises, the nutraceutical market—which includes goods like functional meals, drinks, and dietary supplements that provide health advantages beyond basic nutrition—is growing significantly. As healthcare expenses rise, the population ages, and people want natural and preventative health solutions more and more, this industry is increasing quickly. Further driving market expansion are product formulation innovations and the use of cutting-edge technology for customized nutrition. With its worldwide reach, the nutraceutical industry is expected to keep growing and provide significant chances for research and investment in a number of categories, including vitamins, minerals, probiotics, and herbal supplements.
Richard's entangled aventures in wonderlandRichard Gill
Since the loophole-free Bell experiments of 2020 and the Nobel prizes in physics of 2022, critics of Bell's work have retreated to the fortress of super-determinism. Now, super-determinism is a derogatory word - it just means "determinism". Palmer, Hance and Hossenfelder argue that quantum mechanics and determinism are not incompatible, using a sophisticated mathematical construction based on a subtle thinning of allowed states and measurements in quantum mechanics, such that what is left appears to make Bell's argument fail, without altering the empirical predictions of quantum mechanics. I think however that it is a smoke screen, and the slogan "lost in math" comes to my mind. I will discuss some other recent disproofs of Bell's theorem using the language of causality based on causal graphs. Causal thinking is also central to law and justice. I will mention surprising connections to my work on serial killer nurse cases, in particular the Dutch case of Lucia de Berk and the current UK case of Lucy Letby.
(May 29th, 2024) Advancements in Intravital Microscopy- Insights for Preclini...Scintica Instrumentation
Intravital microscopy (IVM) is a powerful tool utilized to study cellular behavior over time and space in vivo. Much of our understanding of cell biology has been accomplished using various in vitro and ex vivo methods; however, these studies do not necessarily reflect the natural dynamics of biological processes. Unlike traditional cell culture or fixed tissue imaging, IVM allows for the ultra-fast high-resolution imaging of cellular processes over time and space and were studied in its natural environment. Real-time visualization of biological processes in the context of an intact organism helps maintain physiological relevance and provide insights into the progression of disease, response to treatments or developmental processes.
In this webinar we give an overview of advanced applications of the IVM system in preclinical research. IVIM technology is a provider of all-in-one intravital microscopy systems and solutions optimized for in vivo imaging of live animal models at sub-micron resolution. The system’s unique features and user-friendly software enables researchers to probe fast dynamic biological processes such as immune cell tracking, cell-cell interaction as well as vascularization and tumor metastasis with exceptional detail. This webinar will also give an overview of IVM being utilized in drug development, offering a view into the intricate interaction between drugs/nanoparticles and tissues in vivo and allows for the evaluation of therapeutic intervention in a variety of tissues and organs. This interdisciplinary collaboration continues to drive the advancements of novel therapeutic strategies.
Introduction:
RNA interference (RNAi) or Post-Transcriptional Gene Silencing (PTGS) is an important biological process for modulating eukaryotic gene expression.
It is highly conserved process of posttranscriptional gene silencing by which double stranded RNA (dsRNA) causes sequence-specific degradation of mRNA sequences.
dsRNA-induced gene silencing (RNAi) is reported in a wide range of eukaryotes ranging from worms, insects, mammals and plants.
This process mediates resistance to both endogenous parasitic and exogenous pathogenic nucleic acids, and regulates the expression of protein-coding genes.
What are small ncRNAs?
micro RNA (miRNA)
short interfering RNA (siRNA)
Properties of small non-coding RNA:
Involved in silencing mRNA transcripts.
Called “small” because they are usually only about 21-24 nucleotides long.
Synthesized by first cutting up longer precursor sequences (like the 61nt one that Lee discovered).
Silence an mRNA by base pairing with some sequence on the mRNA.
Discovery of siRNA?
The first small RNA:
In 1993 Rosalind Lee (Victor Ambros lab) was studying a non- coding gene in C. elegans, lin-4, that was involved in silencing of another gene, lin-14, at the appropriate time in the
development of the worm C. elegans.
Two small transcripts of lin-4 (22nt and 61nt) were found to be complementary to a sequence in the 3' UTR of lin-14.
Because lin-4 encoded no protein, she deduced that it must be these transcripts that are causing the silencing by RNA-RNA interactions.
Types of RNAi ( non coding RNA)
MiRNA
Length (23-25 nt)
Trans acting
Binds with target MRNA in mismatch
Translation inhibition
Si RNA
Length 21 nt.
Cis acting
Bind with target Mrna in perfect complementary sequence
Piwi-RNA
Length ; 25 to 36 nt.
Expressed in Germ Cells
Regulates trnasposomes activity
MECHANISM OF RNAI:
First the double-stranded RNA teams up with a protein complex named Dicer, which cuts the long RNA into short pieces.
Then another protein complex called RISC (RNA-induced silencing complex) discards one of the two RNA strands.
The RISC-docked, single-stranded RNA then pairs with the homologous mRNA and destroys it.
THE RISC COMPLEX:
RISC is large(>500kD) RNA multi- protein Binding complex which triggers MRNA degradation in response to MRNA
Unwinding of double stranded Si RNA by ATP independent Helicase
Active component of RISC is Ago proteins( ENDONUCLEASE) which cleave target MRNA.
DICER: endonuclease (RNase Family III)
Argonaute: Central Component of the RNA-Induced Silencing Complex (RISC)
One strand of the dsRNA produced by Dicer is retained in the RISC complex in association with Argonaute
ARGONAUTE PROTEIN :
1.PAZ(PIWI/Argonaute/ Zwille)- Recognition of target MRNA
2.PIWI (p-element induced wimpy Testis)- breaks Phosphodiester bond of mRNA.)RNAse H activity.
MiRNA:
The Double-stranded RNAs are naturally produced in eukaryotic cells during development, and they have a key role in regulating gene expression .
Professional air quality monitoring systems provide immediate, on-site data for analysis, compliance, and decision-making.
Monitor common gases, weather parameters, particulates.
2. 2
USER GUIDE
Production protocol
Adeno-associated virus (AAV)
Introduction of AAV
Adeno-associated virus (AAV) is a small single-strand DNA virus infecting human and some other primate species.
Currently, AAV has not known to cause disease and only induces very mild immune responses. As a member of the
family Parvoviridae, wild type AAV requires the assistance of adenovirus or herpesvirus to complete the duplication,
which is the reason why it’s called adeno-associated virus [1,2]. The wild-type AAV2 genome consists of the viral
rep and cap genes (encoding replication and capsid genes, respectively), flanked by inverted terminal repeats (ITRs)
that contain all the cis-acting elements necessary for replication and packaging. The genome of typical AAV2 is
about 4800bp, consisting of two upstream and downstream open read frames (ORFs) which are between two
inverted terminal repeats (ITR) comprising Rep and Cap. ITR is required for synthesis of complementary DNA
strand, while Rep and Cap can be translated into various proteins, including AAV virus cycle essential protein
Rep78, Rep68, Rep52, Rep40 and enveloped protein VP1, VP2, VP3, etc. [3].
The present recombinant AAV (rAAV) vectors are generated by replacing all of the viral genome between the ITRs
with a transcriptional cassette of less than 5 kilobases in length. The resulting construct is then co-expressed with
two other plasmids: 1) an AAV-RC plasmid that provides the Rep and Cap genes in trans (separate from the
ITR/Transgene cassette) and 2) an AAV helper plasmid that harbors the adenoviral helper genes. AAV-293 cells are
used as the packaging cell line since they provide the E1a protein in trans as well. By modifying the Rep and Cap
genes, scientists can control the serotypes to guide the recombinant AAV infection towards certain tissues.
This 3-plasmid co-transfection system liberates the need for adenovirus during AAV production, which greatly
simplifies the purification process.
To date, a total of 12 serotypes of AAV have been described with their unique traits and tropisms [4]. Concerning
high safety, low immunogenicity, long-term expression of exogenous genes, AAV is thought to be the best gene
delivery tool for gene function research in vivo.
Over the past decades, numerous AAV serotypes have been identified with variable tropism. To date, 12 AAV
serotypes and over 100 AAV variants have been isolated from adenovirus stocks or human/nonhuman primate
tissues. Different AAV serotypes exhibit different tropisms, infecting different cell types and tissue types. So,
selecting the suitable AAV serotype is critical for gene delivery to target cells or tissues.
Due to the exhibition of natural tropism towards certain cell or tissue types, rAAV has garnered considerable
attention. Highly prevalent in humans and other primates, several AAV serotypes have been isolated. AAV2, AAV3,
AAV5, AAV6 were discovered in human cells, while AAV1, AAV4, AAV7, AAV8, AAV9, AAV10, AAV11,
AAV12 in nonhuman primate samples [5,6]. Genome divergence among different serotypes is most concentrated on
hypervariable regions (HVRs) of virus capsid, which might determine their tissue tropisms. In addition to virus
capsid, tissue tropisms of AAV vectors are also influenced by cell surface receptors, cellular uptake, intracellular
processing, nuclear delivery of the vector genome, uncoating, and second-strand DNA conversion [7].
3. 3
In order to better improve the infection efficiency and specificity of AAV to target tissues, scientists have genetically
modified the viral capsid, and generated mosaic vectors to create chimeric AAV by swapping domain’s or amino-
acids between serotypes [8,9], which may allow researchers to specifically target cells with certain serotypes to
effectively transduce and express genes in a localized area [10].
Protocol Overview
A schematic overview of recombinant AAV production is shown in Figure 1. The first step is to clone the gene of
interest (GOI) into an appropriate plasmid vector. For most applications, the cDNA of interest is cloned into one of
the ITR/MCS containing vectors. The inverted terminal repeat (ITR) sequences present in these vectors provide all
of the cis-acting elements necessary for AAV replication and packaging.
The recombinant expression plasmid is co-transfected into the AAV-293 cells with pHelper (carrying adenovirus-
derived genes) and pAAV-RC (carrying AAV2 replication and capsid genes), which together supply all of the trans-
acting factors required for AAV replication and packaging in the AAV-293 cells. Recombinant AAV viral particles
are prepared from infected AAV-293 cells and may then be used to infect a variety of mammalian cells.
Upon infection of the host cell, the single-stranded virus must be converted into double-stranded for gene expression.
The AAV virus relies on cellular replication factors for the synthesis of the complementary strand. This conversion
is a limiting step in recombinant gene expression and can be accelerated using adenovirus superinfection or
etoposides, such as camptothecin or sodium butyrate. Whereas these agents are toxic to the target cells and can kill
target cells if left on the cells, so the use of etoposides is only recommended for short-term use or in obtaining viral
titers. Typically, the AAV genome will form high molecular weight concatemers which are responsible for stable
gene expression in cells.
Figure 1. AAV packaging experiment flow chart.
4. 4
Experimental Materials
GeneMedi's AAV Vectors System
GeneMedi's AAV Vector System, also named AAV expression system or AAV packaging plasmid system, is a
powerful tool for in-vivo gene delivery, gene editing, and gene therapy. You can easily produce a recombinant AAV
(rAAV) particle in 293T cell line in high titer using GeneMedi's AAV Vector System. The Genemedi AAV vector
system including multiple AAV expression vector plasmids, AAV helper plasmid and the serotypes-specific AAV
Rep-Cap plasmids (AAV-RC).
GeneMedi's AAV expression vectors have been inserted with different expression cassettes, containing kinds of
verified protomers and reporters including GFP, zsgreen, RFP, mcherry and luciferase. The GeneMedi's AAV
expression vectors have been proved very suitable for unique gene overexpression or shRNA-mediated knock-down
(also called RNAi (RNA interference ). You can also achieve gene knock-out(KO) or gene editing using our Crispr-
cas9-gRNA AAV expression vector.
The serotypes-specific AAV Rep-Cap plasmid (AAV-RC plasmid, or called AAV-RC plasmid) contain the AAV2-
Rep gene with different serotypes of AAV's Cap gene(also called AAV capsids gene).
GeneMedi's AAV Rep-Cap plasmids is including AAV2, AAV5, AAV6, AAV8, AAV9, AAV-PHP.B, AAV-
PHP.eB, AAV PHP.s, AAV-Retro (Retrograde), AAV-Anc80 (L65), AAV-DJ, AAV-DJ8. GeneMedi also supplies
capsid optimized AAV variant including AAV2 variant(Y444F), AAV2 variant (Y272F, Y444F, Y500F, Y730F),
AAV2 variant (Y444F, Y730F, Y500F, Y272F, Y704F, Y252F), AAV2.7m8, AAV8 variant (Y733F), AAV8
variant(Y733F, Y447F), AAV8 variant(Y733F,Y447F,Y275F) and some other engineering AAV serotypes not
mentioned.
Visit https://www.genemedi.net/i/aav-vector-system here for more information about GeneMedi’s AAV vector
system and multiple serotypes of AAV Rep-Cap plasmids.
Bacterium Strain
E. coli strain DH5ɑ is used for amplification of shuttle and backbone vectors.
Packaging Cell Line
AAV-293 is the virus packaging cell line that can facilitate initial production, amplification and titration of rAAV.
Originated from the 293 cell line and established for plaque assays, this cell line was identified to be an easy-to-
handle transfection host.
The complete growth medium of AAV-293 is Dulbecco's Modified Eagle Medium (DMEM) supplemented with
10% Fetal Bovine Serum (FBS) and 1% Penicillin-Streptomycin (Pen-Strep). For a continuous culture, cells should
not exceed 70% confluence to maintain proper characteristics. Usually, starting from cell passage number one,
optimal results can be obtained within 30 passages. Once reached, it is best to start a new culture from another
frozen stock in case of any unexpected mutations and unhealthy growth. Therefore, banking your own AAV-293
frozen stocks is very important to ensure experimental integrity and continuity. Freezing cells at the logarithmic
phase will improve post-thaw viability.
5. 5
Notices:
To maintain cells in a healthier condition and improve production efficiency of AAV, it is recommended to use our
Genemedi anti-mycoplasma reagent, CurePlasmaTM
.
Other Materials and Reagents
Gene of interest
LB broth
Agar and Agarose
Kanamycin
Ampicillin
70 and 100% ethanol
Sterile PBS
Iodixanol
Pluronic-F68
Chlorine bleach
DNA gel apparatus and power supplies
Class II Biosafety Cabinet
37℃ orbital shaker
37℃ bacteria incubator
37℃, 5% CO2 incubator
15- and 50-ml conical tubes
25- and 75-cm2
tissue culture flasks
Cell scrapers
Dry-ice/methanol bath
Liquid nitrogen tank
Low-speed swinging-bucket centrifuge
Microcentrifuge
Centrifuge tube (thick-wall polycarbonate tube with cap)
Packaging and Concentration of rAAV
Construction and Amplification of Plasmids
Constructed rAAV vector plasmids and the backbone vector should be amplified in DH5ɑ and purified by Maxi-
Prep kit to remove endotoxins (note: QIAGEN Plasmid Maxi Kit is recommended). A concentration over 1 µg/µl
and the A260/A280 ratio range between 1.7-1.8 is required for virus packaging. Please be cautious that plasmid
quality would affect the transfection efficiency and titer of product viruses.
Note:
In order to construct vectors quickly and efficiently, it is strongly recommended to use Genemedi - ClonEasyTM
One
Step Cloning Kit(Cat. GM-GC-01/02/03).
Click here to find more about Genemedi - ClonEasyTM
One Step Cloning Kit
6. 6
Transfection of Virus Plasmids into AAV-293 Packaging Cells
a. AAV-293 cells should be prepared at least a day ahead to reach a confluence of 50%-70% monolayer
morphology before transfection.
b. On the day of transfection, DMEM needs to be pre-warmed at 37℃ water bath and LipoGeneTM
transfection
reagent should be equilibrated to room temperature and tapped to mix before use.
c. To prepare viral plasmids for each reaction using a 10-cm dish according to the following table 1:
Table 1. Plasmid and transfection reagent required for transfection.
Component Amount
pAAV-RC 10 μg
pHelper 20 μg
pAAV-GOI 10 μg
LipoGeneTM
100 l
d. Mix plasmids with transfection reagent in DMEM and add drop-wise to pre-seeded AAV-293 cells. Incubate in
37℃, 5% CO2 and refresh with complete culture medium in 6 hours.
Note:
1. A detailed protocol of the transfection reagent can be referred to Genemedi LipoGeneTM
Transfection Reagent
User Manual.
Click here to find more about Genemedi - LipoGeneTM
Transfection Reagent
2. Cells should be in a healthy growth state for use before transfection.
Collection of AAV
a. Around 72 hours after transfection, harvest the cells from the 10 cm plate with a cell scraper.
b. Spin the cells at 1,500g for 5 minutes to collect the cell pellet. Resuspend the cell pellet in 0.5ml lysis buffer (10
mM Tris-HCl (pH8.5), 150 mM NaCl). Freeze/thaw the cell pellet 3 times through a dry ice/ethanol bath and a
37°C water bath to obtain the crude lysate.
c. Spin down the crude lysate at 3,000g for 10 minutes. Collect the supernatant fraction, which contains harvested
rAAV. Keep the virus at -80℃.
Purification of AAV
a. Reagent Preparation:
1× PBS-MK buffer: Dissolve 52.6 mg of MgCl2, and 29.82 mg of KCl in 1× PBS in a final volume of 200 mL.
1 M NaCl/PBS-MK buffer: Dissolve 5.84 g of NaCl in 1× PBS-MK buffer in a final volume of 100 mL.
7. 7
Note: The buffer should be sterilized by passing through a 0.22-μm filter and store at 4 ℃.
15% iodixanol: mix 4.5 mL of 60% iodixanol and 13.5 mL of 1 M NaCl/PBS-MK buffer;
25% iodixanol: mix 5 mL of 60% iodixanol and 7 mL of 1x PBS-MK buffer and 30 μL of phenol red;
40% iodixanol: mix 6.7 mL of 60% iodixanol and 3.3 mL of 1x PBS-MK buffer;
60% iodixanol: mix 10 mL of 60% iodixanol and 45 μL of phenol red.
b. Overlay each solution into a QuickSeal tube in the order (5 mL of 60% iodixanol; 5 mL of 40% iodixanol; 6 mL
of 25% iodixanol; 8 mL of 15% iodixanol) using a 10 mL syringe and an 18 g needle. Carefully add up to 5 mL
of clarified virus supernatant on top of the gradient. Use 1× PBS (or cell lysis buffer) to top off the tube. Seal
the QuickSeal tubes. Centrifuge at 350,000 g for 90 min in a T70i rotor at 10 ℃.
c. Carefully take the QuickSeal tubes out of the rotor and place them in a stable rack.
Note:
Take care to avoid bubbles during purification.
If more centrifugation time is needed, you can alternatively centrifuge for 2 h at 200,000 g at 18 ℃.
Make sure not to disturb the gradient before virus collection.
d. Pierce the QuickSeal tube slightly below the 60-40% interface with an 18 g needle attached to a 10 ml syringe.
The bevel of the needle should be up, facing the 40% iodixanol step. Collect up to 5 ml per tube, and avoid
collecting the proteinaceous material at the 40-25% interface.
Note:
Unless otherwise specified, all AAV viruses are purified with iodixanol gradient ultracentrifugation at 350,000g for
90 min in a T70i rotor at 10℃ to separate contaminants from the impure AAV preparations. The 15% iodixanol step
helps destabilize ionic interactions between macromolecules with the addition of 1M NaCl. The 40% and 25% steps
are used to remove contaminants with lower densities, including empty capsids, while the 60% step acts as a cushion
for genome-containing virions. After several steps of gradient ultracentrifugation, the virus particles will be
enriched.
Concentration of AAV (Ultrafiltration method)
It may be necessary to remove iodixanol (molecular weight: 1,550 Dalton) from the gradient fractions with filtration
or dialysis method either to concentrate the viral particles or avoid interfering with some add-on processes.
a. Pluronic-F68 Preparation:
0.1% Pluronic-F68: 49.5 ml PBS + 500 µl 10% Pluronic F68
0.01% Pluronic-F68: 45 ml PBS + 5 ml 0.1% Pluronic-F68
0.001% Pluronic-F68 with 200mM NaCl: 45 ml PBS + 5 ml 0.01% Pluronic-F68 + 200 mM NaCl
0.001% Pluronic-F68 (formulation buffer): 45 ml PBS + 5 ml 0.01% Pluronic-F68.
8. 8
b. Balance the filter membrane with 15 ml of 0.1% Pluronic F68 and incubate for 10 min at room temperature.
c. Remove the 0.1% Pluronic F68 and add 15 ml of 0.01% Pluronic F68.
d. Centrifuge at 3000 rpm for 5 min at 4 ℃.
e. Discard the filtrates and add 15 ml of 0.001% Pluronic F68 with 200mM NaCl PBS.
f. Centrifuge at 3000 rpm for 5 min at 4 ℃.
g. Discard the filtrates and add virus purifications.
h. Centrifuge at 3500 rpm for 8 min at 4 ℃, discard the flow-through.
i. Replenish more virus purifications and spin 3500 rpm for 4 min at 4°C, discard the filtrates. Repeat this step as
needed.
j. Utilize a P1000 to pipette up and down to wash off the filter wall to recover as much virus as possible.
k. Keep the concentrates at 4 ℃ for short term (less than one week), or in small aliquots and keep at -80 ℃ for long
term usage.
Note:
1. It is difficult to remove Iodixanol. Add more formulation buffer and virus purifications and pipet back and forth
a few times in order to mix the iodixanol settled at the bottom or wall of the column into the solution after each
centrifugation.
2. Concentrating on a minimum of 500 µl is recommended. If the concentrate volume is less than 500 µl, bring up
the volume with formulation buffer.
Quality Assurance of rAAV
AAV capsid contains VR1 82kDa, VR2 72kDa and VR3 62kDa, which can be detected using the method of
polyacrylamide gel electrophoresis (PAGE) followed by silver staining or Coomassie blue staining. Pure AAV
should display only three major protein bands, such as the following virus purified in Genemedi shown in Figure 2.
We guarantee the purity of the AAV virus based on the specification that we give for different services.
Figure 2. Purity of purified AAV virus.
Titer Detection of rAAV
AAV titers are determined by real-time quantitative PCR using primers targeted the ITR. The amplicons are detected
using SYBR green technology. Titer values are then determined by comparison to a standard curve of a plasmid
sample of known concentration. An example of the Ct value of the standard sample and sample to be tested is shown
in table 2, while the standard curve is displayed in figure 3.
9. 9
Table 2. Ct value of standard and sample in a typical absolute quantification process.
Set the average Ct value of each group as Y-axis, the logarithm of corresponding group as X-axis. Substitute the
average Ct value of samples to be tested into formula, obtaining X = 7.45. Substitute the AAV virus titer calculation
formula: 10x
× 40000 vg/ml= 107.45
× 40000=1.1 × 1012
vg/ml.
Figure 3. Standard curve in absolute quantification.
Cell Infection Test of AAV
After AAV titer detection, the infection activity needs to be evaluated before animal experiments. Test the
expression of target gene by infecting cells, such as 293T, CHO. MOI will be controlled ranging from 104
to 105
(MOI is multiplicity of infection, namely the number of virus particles needed for infecting a cell). The detailed
AAV infection protocol can be found in the AAV User Manual.
Safe Use of AAV
1. AAV related experiments should be conducted in biosafety level 2 facilities (BL-2 level).
2. Please equip with lab coat, mask, gloves completely, and try your best to avoid exposing hand and arm.
3. Be careful of splashing virus suspension. If biosafety cabinet is contaminated with virus during operation, scrub
the table-board with solution comprising 70% alcohol and 1% SDS immediately. All tips, tubes, culture plates,
medium contacting virus must be soaked in chlorine-containing disinfectant before disposal.
4. If centrifuging is required, a centrifuge tube should be tightly sealed. Seal the tube with parafilm before
centrifuging if condition allowed.
Standard Copy Number (vg/ml) Ct value 1 Ct value 2 Ct value 3
Standard_1 1010
4.51 4.32 4.42
Standard_2 109
7.21 7.61 7.25
Standard_3 108
10.97 10.55 10.67
Standard_4 107
14.19 14.38 14.35
Standard_5 106
17.75 17.58 17.68
AAV Sample 12.78 12.65 12.81
10. 10
5. AAV related animal experiments should also be conducted in BL-2 level.
6. AAV associated waste materials need to be specially collected and autoclaved before disposal.
7. Wash hands with sanitizer after experiment.
Storage and Dilution of AAV
Storage of AAV
Virus can be stored at 4°C for a short time (less than a week) before using after reception. Since AAV viruses are
sensitive to freeze-thawing and the titer drops with repeated freeze-thawing, aliquot viral stock should be stored at -
80°C freezer immediately upon arrival for long-term usage. While virus titer redetection is suggested before using if
the AAV viruses have been stored for more than 12 months.
Dilution of AAV
Dissolve virus in ice water if virus dilution is required. After dissolving, mix the virus with medium, sterile PBS or
normal saline solution, keeping at 4°C (using within a week).
Precautions
· Avoid AAV exposure to environmental extremes (pH, chelating agents like EDTA, temperature, organic solvents,
protein denaturants, strong detergents, etc.)
· Avoid introducing air into the AAV samples during vortex, blowing bubbles or similar operations, which may
result in protein denaturation.
· Avoid repeated freezing and thawing.
· Avoid exposing to “regular” plastics (especially polystyrene or hydrophobic plastics) for prolonged periods in
liquid phase. Most AAV viruses are very sticky and loss can occur if exposed to regular plastics, including tubes,
cell culture plates, pipette tips, if not frozen. It is best to store AAV in siliconized or low protein binding tubes.
Pluronic F-68 used at 0.01%-0.1% in the formulation buffer will minimize sticking if regular plastics are used.
· Avoid diluting AAV into low salt solution. Some AAV serotypes, such as AAV2, aggregates in low salt solution,
which will be non-infectious.
11. 11
References
1. Atchison RW, BC Casto and WM Hammon. (1965). Adenovirus-Associated Defective Virus Particles. Science 149:754-6.
2. Hoggan MD, NR Blacklow and WP Rowe. (1966). Studies of small DNA viruses found in various adenovirus preparations: physical, biological, and
immunological characteristics. Proc Natl Acad Sci U S A 55:1467-74.
3. Weitzman MD and RM Linden. (2011). Adeno-associated virus biology. Methods Mol Biol 807:1-23.
4. Schmidt M, A Voutetakis, S Afione, C Zheng, D Mandikian and JA Chiorini. (2008). Adeno-associated virus type 12 (AAV12): a novel AAV serotype with
sialic acid- and heparan sulfate proteoglycan-independent transduction activity. J Virol 82:1399-406.
5. Gao G, LH Vandenberghe, MR Alvira, Y Lu, R Calcedo, X Zhou and JM Wilson. (2004). Clades of Adeno-associated viruses are widely disseminated in
human tissues. J Virol 78:6381-8.
6. Vandenberghe LH, JM Wilson and G Gao. (2009). Tailoring the AAV vector capsid for gene therapy. Gene Ther 16:311-9.
7. Wu Z, A Asokan and RJ Samulski. (2006). Adeno-associated virus serotypes: vector toolkit for human gene therapy. Mol Ther 14:316-27.
8. Hauck B, L Chen and W Xiao. (2003). Generation and characterization of chimeric recombinant AAV vectors. Mol Ther 7:419-25.
9. Rabinowitz JE, DE Bowles, SM Faust, JG Ledford, SE Cunningham and RJ Samulski. (2004). Cross-dressing the virion: the transcapsidation of adeno-
associated virus serotypes functionally defines subgroups. J Virol 78:4421-32.
10. Choi VW, DM McCarty and RJ Samulski. (2005). AAV hybrid serotypes: improved vectors for gene delivery. Curr Gene Ther 5:299-310.
Related products
1. AAV packaging system
More details please visit: https://www.genemedi.net/i/aav-vector-system
2. AAV Promise-ORFTM
:
Sequence-verified CDNA clones in AAV and mammalian expression vectors.
More details please visit: https://www.genemedi.net/l/aav-plasmid
3. AAV custom production
More details please visit: https://www.genemedi.net/i/adeno-associated-virus-aav-customized-production-service